medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2007, Number 4

<< Back Next >>

Rev Invest Clin 2007; 59 (4)

Smoking habit: Physiopathology and prevention

Liras A, Martín S, García R, Maté I, Padilla V

Language: Spanish
References: 37
Page: 278-289
PDF size: 101.33 Kb.


ABSTRACT

Smoking has a history almost as old as the own leaf of the tobacco, although in fact the act to smoke was restored in the general society after the discovery of America, considering itself even beneficial for the health, but fundamentally like a social and conventional conduct of the high nobility. In XVI century the first detractors began to appear but it was necessary many years to arrive the XX century when it was begun to relate the habit to tobacco and cancer, some years after the commercialization at industrial level of this habit. At the present the social awareness is tried towards the sanitary prevention. The declaration of Warsaw, the Marco Agreement and other sanitary measures forehead the habit to tobacco, are clear examples of this medical-social restlessness that tries to exile the smoking as a social, conventional and good seen conduct to try a prevention and a greater quality of life of the individuals.


REFERENCES

  1. de las Casas Fray Bartolomé. Historia de las Indias. [Consultado 22/05/2007]. Disponible en: http://www.cervantesvirtual.com/servlet/SirveObras/02586281999194239932268/index.htm

  2. Nicot Jean. [Consultado 22/05/2007]. Disponible en: http://www.nimausensis.com/Gard/ImageMois/JeanNicot/JeanNicot.htm

  3. Redmond DE Jr. Tobacco and cancer: the first clinical report, 1761. N Engl J Med 1970; 282: 18-23.

  4. Davey G, Egger M. The first reports on smoking and lung cancer–why are they consistently ignored? Boletín de la OMS 2005; 83. [Consultado 22/05/2007]. Disponible en: http://www.scielosp.org/scielo.php?pid=S0042-96862005001000020&script=sci_arttext&tlng=en

  5. Doll Richard. [Consultado 22/05/2007]. Disponible en: http://www.scielosp.org/scielo.php?pid=S0036-36342005000400010&script=sci_arttext.

  6. Legislación sobre el uso del tabaco. Ministerio de Sanidad y Consumo. [Consultado 22/05/2007]. Disponible en: http://www.msc.es/ciudadanos/proteccionSalud/adolescencia/tabaco/legislacion.htm

  7. Organización Mundial de la Salud. Declaración de Varsovia para una Europa libre de Tabaco. [Consultado 22/05/2007]. Disponible en: http://www.who.int/gb/fctc/PDF/inb4/sinb44a1.pdf.

  8. Organización Mundial de la Salud. Convenio Marco para el control del Tabaco. [Consultado 22/05/2007]. Disponible en: http://www.paho.org/Spanish/DD/PUB/sa56r1.pdf

  9. Hansen MD. Estrategias de la industria del tabaco en España: grupos de presión, marketing y publicidad al servicio de un producto adictivo. Med Clin 2005; 124: 220-2.

  10. Marcos T, Godás T, Corominas J. Tratamiento de sustitución de nicotina frente a reducción progresiva en la deshabituación tabáquica. Med Clin 2004; 123: 127-30.

  11. Barrueco M, Alonso A, González-Sarmiento R. Bases genéticas del hábito tabáquico. Med Clin 2005; 124: 223-8.

  12. Cami J, Farre M. Drug addiction. N Engl J Med 2003; 349: 975-86.

  13. Zamora A, Elosua R. Marrugat J. El tabaco como factor de riesgo cardiovascular en las poblaciones mediterráneas. Clin Invest Arterioscl 2004; 16: 207-20.

  14. Asociación Española contra el Cáncer. Radiografía del cigarrillo. [Consultado 22/05/2007]. Disponible en: http://www.aecc.es/ESP/Informacion+Cancer/Consejos+de+salud/Tabaco/Radiografia+del+cigarrillo.htm

  15. Özlü T, Bülbül Y. Smoking and lung cancer. Tüberküloz ve Toraks Dergisi 2005; 53: 200-9. [Consultado 22/05/2007]. Disponible en: http://www.journalagent.com/pubmed/linkout.asp?ISSN=0494-1373&PMID=16100660

  16. Saijo N. Recent trends in the treatment of advanced lung cancer. Cancer Sci 2006; 97: 448-52.

  17. Machida EO, Brock MV, Hooker CM, Nakayama J, Ishida A, Amano J, et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 2006; 66: 6210-8.

  18. Lopez MJ, Nebot M, Salles J, Serrahima E, Centrich F, Juarez O, et al. Measurement of exposure to environmental tobacco smoke in education centers, health centers, transport facilities and leisure places. Gac Sanit 2004; 18: 451-7.

  19. Carrión-Valero F. Tabaquismo pasivo en el lugar de trabajo. Med Clin 2006; 126: 17-8.

  20. Miró O, Nogué S. Acerca del cálculo de los riesgos del tabaquismo pasivo. Med Clin 2006; 127: 76.

  21. Simonato L, Agudo A, Ahrens W, Benhamou E, Benhamou S, Boffetta P, et al. Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogeneity. Int J Cancer 2001; 91: 876-87.

  22. Cassidy A, Myles JP, Liloglou T, Duffy SW, Field JK. Defining high-risk individuals in a population-based molecularepidemiological study of lung cancer. Int J Oncol 2006; 28: 1295-301.

  23. Liras A. Reparación del ADN en el control de las enfermedades. Biología Org 2004; 15: 1-3. [Consultado 22/05/2007]. Disponible en: http://www.biologia.org/?pid=5000&id=79&page=0

  24. Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, et al. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 2006; 52: 9-14.

  25. Hagiwara N, Mechanic LE, Trivers GE, Cawley HL, Taga M, Bowman ED, et al. Quantitative Detection of p53 Mutations in Plasma DNA from Tobacco Smokers. Cancer Res 2006; 66: 8309-17.

  26. Schabath MB, Wu X, Wei Q, Li G, Gu J, Spitz MR. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 158-61.

  27. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006; 27: 110-7.

  28. Yokoyama T, Kondo M, Goto Y, Fukui T, Yoshioka H, Yokoi K, et al. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 2006; 97: 753-9.

  29. Chen JT, Lin TS, Chow KC, Huang HH, Chiou SH, Chiang SF, et al. Cigarette smoking induces over-expression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol 2006; 34: 264-73.

  30. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006; 8: 30-8.

  31. Senju M, Sueoka N, Sato A, Iwanaga K, Sakao Y, Tomimitsu S, et al. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol 2006; 132: 150-8.

  32. Thomas L, Doyle LA, Edelman MJ. Lung Cancer in Women: Emerging Differences in Epidemiology, Biology, and Therapy. Chest 2005; 128; 370-81. [Consultado 22/05/2007]. Disponible en: http://www.chestjournal.org/cgi/reprint/128/1/370

  33. Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002; 37: 153-9.

  34. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, et al. Ethnic and racial differences in the smoking- related risk of lung cancer. N Engl J Med 2006; 354: 333-42.

  35. Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004; 96: 99-106. [Consultado 22/05/2007]. Disponible en: http://jncicancerspectrum.oxfordjournals.org/cgi/content/full/jnci;96/2/99

  36. Vacuna antitabáquica (NicVAX(TM) de Nabi Biopharmaceuticals. [Consultado 22/05/2007]. Disponible en: http://www.sedet.es/secciones/noticias/noticias.php?id_categoria=5&anyo=2005&mes=7

  37. Córdoba R, Altisent R. Ética clínica y tabaco. Med Clin 2004; 122: 262-6.




2020     |     www.medigraphic.com